| Literature DB >> 31996239 |
John G Dreisbach1,2, Shobhit Mathur1,2, Christian P Houbois1,2, Erwin Oechslin3,4, Heather Ross3,4, Kate Hanneman1,2, Bernd J Wintersperger5,6.
Abstract
BACKGROUND: Investigation of the myocardial strain characteristics of the left ventricular non-compaction (LVNC) phenotype with cardiovascular magnetic resonance (CMR) feature tracking.Entities:
Keywords: Cardiovascular magnetic resonance; Feature tracking; Isolated noncompaction of the ventricular myocardium; Myocardial strain; Ventricular dysfunction
Mesh:
Year: 2020 PMID: 31996239 PMCID: PMC6990516 DOI: 10.1186/s12968-020-0599-3
Source DB: PubMed Journal: J Cardiovasc Magn Reson ISSN: 1097-6647 Impact factor: 5.364
Fig. 1Retrospective Patient Identification. CMR = cardiovascular magnetic resonance; LVNC = left ventricular non-compaction cardiomyopathy; bSSFP = balanced steady-state free precession
Fig. 2CMR Diagnostic Criteria for LVNC. a CMR short-axis cine bSSFP image of the apical LV demonstrating severely thickened myocardium with prominent trabeculations and deep intertrabecular recesses in a 49-year-old female with a history of ventricular tachycardia and LVNC phenotype. b Measurement of the maximum non-compacted (NC): compacted myocardium diameter ratio. c Standard epicardial contours and endocardial contours at the border of the compacted and NC myocardium for measurement of the compacted myocardial mass. d Endocardial contours at the border of the NC myocardium and non-trabeculated cavity for measurement of the global myocardial mass (compacted and non-compacted myocardial mass). CMR = cardiovascular magnetic resonance; LVNC = left ventricular non-compaction cardiomyopathy; bSSFP = balanced steady-state free precession; LV = left ventricle
Demographic Characteristics and LV Volumetrics
| All patients and volunteers | Subgroup A | Subgroup B | Subgroup C | Subgroup D | A vs. B | A vs. C | A vs. D | C vs. D | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| All LVNC phenotype patients | All healthy subjects | LVNC phenotype patients (normal LV volumetrics) | Healthy subjects (normal LV volumetrics) | Healthy subjects (normal LV volumetrics, not meeting any LVNC criteria) | Healthy subjects (normal LV volumetrics, meeting one or more LVNC criteria) | ||||||
| ( | ( | ( | ( | ( | ( | ||||||
| Malea | 30 (51%) | 16 (44%) | 0.673 | 9 (36%) | 15 (44%) | 4 (25%) | 11 (61%) | 0.598 | 0.513 | 0.130 | 0.045 |
| Age (years)b | 40.3 (28.4, 50.5) | 39.0 (30.2, 46.6) | 0.866 | 33.2 (22.7, 42.5) | 39.0 (30.4, 47) | 44.7 (38.0, 57.9) | 34.3 (30.0, 40.8) | 0.089 | 0.017 | 0.588 | 0.012 |
| BSA (m2)c | 1.87 (1.64, 2.08) | 1.82 (1.63, 2.02) | 0.863 | 1.69 (1.55, 1.87) | 1.82 (1.63, 1.99) | 1.72 (1.63, 1.89) | 1.94 (1.71, 2.05) | 0.118 | 0.527 | 0.045 | 0.198 |
| Heart Rate (bpm)b | 65 (56, 74) | 62 (59, 706) | 0.466 | 66 (57, 72) | 63 (59, 71) | 64 (60, 70) | 62 (56, 71) | 0.545 | 0.820 | 0.445 | 0.469 |
| EDV (ml)b | 173 (143, 203) | 152 (122, 180) | 0.054 | 143 (127, 155) | 145 (122, 176) | 137 (120, 155) | 171 (122, 197) | 0.439 | 0.669 | 0.102 | 0.079 |
| EDVI (ml/m2)b | 93.0 (80.7, 102.9) | 84.2 (72.5, 95.6) | 0.036 | 83.0 (74.8, 91.7) | 83.8 (71.4, 92.6) | 78.4 (69.3, 85.5) | 88.3 (81.1, 102.1) | 0.902 | 0.181 | 0.153 | 0.032 |
| ESV (ml)b | 79 (58, 103) | 54 (45, 69) | < 0.001 | 58 (53, 70) | 53 (44, 68) | 50 (40, 56) | 68 (48, 74) | 0.390 | 0.019 | 0.431 | 0.027 |
| ESVI (ml/m2)b | 42.4 (33.6, 53.1) | 30.2 (25.7, 37.8) | < 0.001 | 34.1 (31.1, 39.2) | 30.1 (25.6, 36.0) | 29.8 (22.8, 30.6) | 33.9 (25.8, 39.6) | 0.051 | 0.002 | 0.787 | 0.019 |
| SV (ml)b | 86 (76, 107) | 95 (77, 118) | 0.121 | 80 (74, 91) | 93 (77, 116) | 87 (795, 99) | 103 (76, 122) | 0.051 | 0.219 | 0.046 | 0.178 |
| SVI(ml/m2)c | 49.2 (41.3, 52.7) | 54.1 (46.8, 59.0) | 0.796 | 49.5 (43.9, 52.6) | 53.3 (46.7, 58.3) | 50.1 (46.6, 55.2) | 56.5 (47.0, 59.9) | 0.033 | 0.205 | 0.008 | 0.125 |
| EF (%)b | 54 (49, 59) | 63 (60, 66) | < 0.001 | 59 (57, 60) | 63 (60, 66) | 65 (63, 68) | 61 (59, 64) | < 0.001 | < 0.001 | 0.004 | 0.023 |
| CO (l/min)b | 5.66 (4.74, 6.96) | 5.85 (4.90, 7.10) | 0.485 | 5.13 (4.53, 6.13) | 5.85 (4.91, 7.07) | 5.60 (4.96, 6.75) | 6.30 (4.89, 7.78) | 0.163 | 0.364 | 0.161 | 0.512 |
| LVM (g)b | 105 (82, 136) | 98 (84, 128) | 0.747 | 82 (67, 99) | 98 (83, 128) | 93 (81, 102) | 108 (84, 142) | 0.018 | 0.181 | 0.011 | 0.121 |
| LVMI (g/m2)b | 54.9 (48.9, 66.2) | 55.4 (50.1, 65.5) | 0.777 | 49.5 (43.7, 54.2) | 55.0 (50.0, 64.7) | 52.0 (48.9, 56.8) | 55.8 (50.1, 69.7) | 0.012 | 0.157 | 0.007 | 0.113 |
Data presented as n (%) or median (IQR)
LV left ventricle, LVNC left ventricular non-compaction cardiomyopathy, BSA body surface area, bpm beats per minute, EDV end-diastolic volume, EDVI end-diastolic volume indexed to BSA, ESV end-systolic volume, ESVI end-systolic volume indexed to BSA, SV stroke volume, SVi stroke volume indexed to BSA, EF ejection fraction, CO cardiac output, LVM left ventricular mass, LVMI LVM indexed to BSA
aFisher’s exact test
bWilcoxon rank sum test
cIndependent samples t-test
CMR Diagnostic Criteria for LVNC
| All patients and healthy subjects | Subgroup A | Subgroup B | Subgroup C | Subgroup D | A vs. B | A vs. C | A vs. D | C vs. D | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| All LVNC phenotype patients | All healthy subjects | LVNC phenotype patients (normal LV volumetrics) | Healthy subjects (normal LV volumetrics) | Healthy subjects (normal LV volumetrics, not meeting any LVNC criteria) | Healthy subjects (normal LV volumetrics, meeting one or more LVNC criteria) | ||||||
| ( | ( | ( | ( | ( | ( | ||||||
| Number of NC segmentsb | 8 (6, 9) | 0 (0, 0) | < 0.001 | 8 (6, 9) | 0 (0, 0) | 0 (0, 0) | 0 (0, 1) | < 0.001 | < 0.001 | < 0.001 | 0.013 |
| Maximum NC:C ratiob | 3.8 (3.0, 4.3) | 1.2 (0.9, 1.6) | < 0.001 | 3.5 (3.2, 4.3) | 1.1 (0.9, 1.3) | 1.0 (0.8, 1.2) | 1.2 (0.9, 2.5) | < 0.001 | < 0.001 | < 0.001 | 0.182 |
| NC:C > 2.3a | 59 (100%) | 7 (19.4%) | < 0.001 | 25 (100%) | 6 (17.7%) | 0 (0%) | 6 (33.3%) | < 0.001 | < 0.001 | < 0.001 | 0.020 |
| Percentage of NC mass (%)b | 40.8 (35.7, 45.9) | 19.5 (17.2, 23.3) | < 0.001 | 42.2 (38.7, 47.1) | 19.3 (17.1, 23.6) | 17.2 (14.8, 18.5) | 23.3 (20.1, 30.7) | < 0.001 | < 0.001 | < 0.001 | < 0.001 |
| NC mass > 20%a | 59 (100%) | 16 (44.4%) | < 0.001 | 25 (100%) | 14 (41.2%) | 0 (0%) | 14 (77.8%) | < 0.001 | < 0.001 | 0.025 | < 0.001 |
| NC mass > 25%a | 59 (100%) | 5 (13.9%) | < 0.001 | 25 (100%) | 5 (14.7%) | 0 (0%) | 5 (27.8%) | < 0.001 | < 0.001 | < 0.001 | 0.046 |
| NC mass/BSA (g/m2)b | 36.1 (32.3, 42.9) | 13.6 (10.5, 17.2) | < 0.001 | 35.1 (30.9, 39.2) | 12.7 (10.4, 17.0) | 10.0 (8.8, 11.6) | 17.0 (15.0, 23.7) | < 0.001 | < 0.001 | < 0.001 | < 0.001 |
| NC mass > 15 g/m2a | 59 (100%) | 15 (41.7%) | < 0.001 | 25 (100%) | 13 (38.2%) | 0 (0%) | 13 (72.2%) | < 0.001 | < 0.001 | 0.009 | < 0.001 |
Data presented as n (%) or median (IQR)
NC:C >2.3 = maximum end-diastolic non-compacted (NC): compacted (C) myocardium diameter ratio >2.3 in at least one segment.
CMR cardiovascular magnetic resonance, LVNC left ventricular non-compaction cardiomyopathy, LV left ventricle, NC non-compacted myocardium, C compacted myocardium, BSA body surface area
aFisher’s exact test
bWilcoxon rank sum test
Strain and Torsion
| All patients and healthy subjects | Subgroup A | Subgroup B | Subgroup C | Subgroup D | A vs. B | A vs. C | A vs. D | C vs. D | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| All LVNC phenotype patients | All healthy volunteers | LVNC phenotype patients (normal LV volumetrics) | Healthy subjects (normal LV volumetrics) | Healthy subjects (normal LV volumetrics, not meeting any LVNC criteria) | Healthy subjects (normal LV volumetrics, meeting one or more LVNC criteria) | ||||||
| ( | ( | ( | ( | ( | ( | ||||||
| GRS (%)a | 26.4 (21.8, 32.7) | 37.1 (33.4, 43.1) | < 0.001 | 31.2 (28.2, 34.7) | 37.5 (34.2, 43.5) | 40.2 (35.5, 44.3) | 35.8 (33.1, 40.8) | < 0.001 | < 0.001 | 0.006 | 0.103 |
| Basal RS (%)a | 26.8 (21.2, 30.7) | 34.6 (31.0, 39.1) | < 0.001 | 28.8 (27.4, 36.1) | 34.6 (31.4, 39.1) | 35.3 (33.9, 40.9) | 32.0 (30.3, 35.6) | 0.004 | 0.002 | 0.112 | 0.044 |
| Mid RS (%)a | 23.9 (19.7, 28.9) | 29.9 (24.9, 35.9) | < 0.001 | 28.5 (24.7, 31.8) | 30.5 (25.8, 36.2) | 32.4 (29.5, 37.1) | 26.6 (24.0, 35.5) | 0.065 | 0.008 | 0.516 | 0.087 |
| Apical RS (%)a | 29.4 (24.0, 37.3) | 46.4 (40.1, 56.4) | < 0.001 | 33.3 (29.4, 42.2) | 47.3 (41.8, 58.2) | 49.2 (42.8, 59.8) | 45.6 (40.3, 51.4) | < 0.001 | < 0.001 | 0.002 | 0.451 |
| GCS (%)b | −16.5 (−14.7, −18.6) | −20.5 (−19.1, −22.1) | < 0.001 | −18.5 (−16.8, −19.8) | −20.6 (−19.3, −22.1) | −21.5 (−20.1, −22.9) | −20.0 (−18.8, −21.7) | < 0.001 | < 0.001 | 0.005 | 0.073 |
| Basal CS (%)b | −16.3 (−14.2, −18.1) | −19.6 (−18.4, −21.1) | < 0.001 | −17.4 (−16.6, −20.0) | −19.6 (−18.4, −21.2) | −20.1 (−19.3, −21.7) | −18.5 (− 18.2, − 20.0) | 0.003 | 0.002 | 0.072 | 0.027 |
| Mid CS (%)b | −15.5 (−13.4, −17.8) | − 18.3 (− 16.1, − 20.3) | < 0.001 | −17.5 (− 16.1, − 18.9) | − 18.6 (− 16.5, − 20.4) | − 19.4 (− 18.1, − 21.0) | −17.2 (−15.9, − 19.9) | 0.061 | 0.005 | 0.658 | 0.079 |
| Apical CS (%)b | −17.8 (−15.4, − 19.9) | −23.4 (− 21.9, −25.9) | < 0.001 | − 19.4 (− 17.8, − 22.2) | −23.7 (− 22.3, − 26.3) | −24.4 (− 22.6, −26.6) | −23.0 (− 22.0, −24.5) | < 0.001 | < 0.001 | < 0.001 | 0.270 |
| GLS (%)b | −14.6 (−12.9, − 16.5) | − 17.1 (− 16.1, − 18.7) | < 0.001 | − 16.4 (− 15.3, − 17.3) | −17.1 (− 16.2, − 19.0) | −17.2 (− 16.7, − 19.6) | − 16.9 (− 16.1, − 18.3) | 0.011 | 0.009 | 0.099 | 0.143 |
| 4-chamber LS (%)b | −14.7 (− 12.9, − 16.9) | −18.1 (− 16.8, − 19.5) | < 0.001 | −16.0 (− 14.6, − 16.6) | −16.7 (− 15.4, − 18.4) | − 17.6 (− 16.2, − 20.4) | −16.2 (− 15.0, − 17.3) | 0.021 | 0.003 | 0.313 | 0.032 |
| 3-chamber LS (%)b | −14.7 (− 12.5, − 16.5) | −17.5 (− 15.9, − 19.1) | < 0.001 | − 16.4 (− 14.9, − 17.9) | − 17.6 (− 16.1, − 19.1) | −17.8 (− 16.4, − 19.3) | − 17.3 (− 16.0, − 18.6) | 0.046 | 0.048 | 0.168 | 0.427 |
| 2-chamber LS (%)b | −14.8 (−13.2, − 16.7) | − 17.6 (− 16.3, − 19.3) | < 0.001 | − 16.7 (− 14.8, − 18.5) | −17.6 (− 16.4, − 19.2) | −17.7 (− 16.3, − 18.7) | −17.5 (− 16.4, − 19.4) | 0.034 | 0.109 | 0.055 | 0.717 |
| Global Torsion (°/cm)b | 1.01 (0.68, 1.43) | 0.94 (0.74, 1.54) | 0.765 | 1.23 (0.99, 1.47) | 0.98 (0.78–1.55) | 1.01 (0.86, 1.75) | 0.93 (0.71, 1.42) | 0.470 | 0.852 | 0.184 | 0.178 |
Data presented as median (IQR)
LVNC left ventricular non-compaction cardiomyopathy, LV left ventricle, GRS global radial strain, RS radial strain, GCS global circumferential strain, CS circumferential strain, GLS global longitudinal strain, LS longitudinal strain
aIndependent samples t-test
bWilcoxon rank sum test
Fig. 3Strain: Box Plots. Box plots comparing a GRS, b GCS and c GLS between: all LVNC phenotype patients and healthy subjects; Subgroup A vs. B (LVNC phenotype patients with normal LV volumetrics and healthy subjects with normal LV volumetrics); Subgroup A vs. C (LVNC phenotype patients with normal LV volumetrics and healthy subjects with normal LV volumetrics not meeting any CMR diagnostic criteria for LVNC); Subgroup A vs. D (LVNC phenotype patients with normal LV volumetrics and healthy subjects with normal LV volumetrics meeting at least one of the CMR diagnostic criteria for LVNC); Subgroup C vs. D (healthy subjects with normal LV volumetrics meeting none of the CMR diagnostic criteria for LVNC and those meeting at least one criteria). GRS = global radial strain; GCS = global circumferential strain; GLS = global longitudinal strain; LVNC = left ventricular non-compaction cardiomyopathy; LV = left ventricle; CMR = cardiovascular magnetic resonance
ROC Analysis
| All LVNC phenotype patients and all healthy subjects | Subgroup A vs. B | Subgroup A vs. C | Subgroup A vs. D | Subgroup C vs. D | |
|---|---|---|---|---|---|
| LVNC phenotype patients (normal LV volumetrics) and healthy subjects (normal LV volumetrics) | LVNC phenotype patients (normal LV volumetrics) and healthy subjects (normal LV volumetrics, not meeting any LVNC criteria) | LVNC phenotype patients (normal LV volumetrics) and healthy subjects (normal LV volumetrics, meeting one or more LVNC criteria) | Healthy subjects (normal LV volumetrics, not meeting any LVNC criteria) and healthy subjects (normal LV volumetrics, meeting one or more LVNC criteria) | ||
| AUC | AUC | AUC | AUC | AUC | |
| GRS | 0.85 (0.78, 0.92) | 0.78 (0.66, 0.90) | 0.84 (0.70, 0.97) | 0.72 (0.57, 0.88) | 0.65 (0.46, 0.84) |
| GCS | 0.86 (0.79, 0.93) | 0.80 (0.69, 0.91) | 0.86 (0.74, 0.98) | 0.76 (0.61, 0.90) | 0.68 (0.49, 0.87) |
| GLS | 0.83 (0.75, 0.91) | 0.69 (0.56, 0.83) | 0.75 (0.59, 0.90) | 0.65 (0.48, 0.82) | 0.65 (0.46, 0.84) |
Data presented as AUC (95% CI)
LVNC left ventricular non-compaction cardiomyopathy, LV left ventricle, ROC receiver operating characteristic, AUC area under the curve, GRS global radial strain, GCS global circumferential strain, GLS global longitudinal strain, CI confidence interval
Fig. 4Strain: ROC Analysis. ROC curves for GRS, GCS and GLS comparing a All LVNC phenotype patients and healthy subjects ; b Subgroup A vs. B (LVNC phenotype patients with normal LV volumetrics and healthy subjects with normal LV volumetrics); c Subgroup A vs. C (LVNC phenotype patients with normal LV volumetrics and healthy subjects with normal LV volumetrics not meeting any CMR diagnostic criteria for LVNC); d Subgroup A vs. D (LVNC phenotype patients with normal LV volumetrics and healthy subjects with normal LV volumetrics meeting at least one of the CMR diagnostic criteria for LVNC). ROC = receiver operating characteristic; GRS = global radial strain; GCS = global circumferential strain; GLS = global longitudinal strain; LVNC = left ventricular non-compaction cardiomyopathy; LV = left ventricle; CMR = cardiovascular magnetic resonance